Publication | Closed Access

Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

Signal TransductionAutoimmune DiseaseCell RegulationMedicineReceptor Tyrosine KinaseImmunologySignal TransducerGain-of-function MutationsTranscription 1Cell BiologyCell Signaling